Effects of iodinated contrast agent on HU-based dose calculation and dose delivered in iridium-192 high-dose-rate brachytherapy

Dr. Christian Scherf, PhD1, PD Dr. Ulla Ramm, PhD1, Thomas Stein, MSc2, Martin Trommel, MSc1, PD Dr. Nikolaos Tselis, MD1, Dr. Georgios Chatzikonstantinou, MD1, Dr. Markus Diesenhardt, MD1, Prof. Dr. Claus Rödel, MD1, Dr. Janett Köhn, PhD1, Dr. Jörg Licher, PhD1

*Christian Scherf and Ulla Ramm contributed equally to this work.

1 Department of Radiation Oncology, University Hospital, Goethe University, Frankfurt, Germany, 2 University of Applied Sciences Ansbach, Ansbach, Germany

Abstract

**Purpose:** This study compares the effect of iodinated contrast agent on Hounsfield unit (HU)-based TG-186 dose calculation vs. delivered dose for high-dose-rate (HDR) iridium-192 brachytherapy using a phantom model.

**Material and methods:** A reservoir filled with a diluted contrast agent was placed inside a water phantom. A single steel needle applicator was centrally positioned inside the reservoir. Computed tomography (CT) datasets of five different contrast agent dilutions (25 to 300 mg/ml iodine concentration) were acquired, and dose calculations were performed with TG-186 ACE dose calculation formalism of Oncentra® Brachy (Elekta). The dose was measured with a PinPoint® ionization chamber (PTW) inside the contrast agent. ACE calculated and measured data were compared.

**Results:** For the different contrast agent dilutions, averaged Hounsfield units from 453 ±21 to 2623 ±221 were obtained. Electron densities derived from CT data were significantly higher than corresponding electron densities calculated from chemical compositions. Consequently, the measured dose was higher than corresponding HU-based calculated dose. Relative deviation ranged from 2.5% to 7% per 10 mm penetration depth, depending on contrast agent concentration.

**Conclusions:** The application of HU-based TG-186 dose formalisms in the presence of high-Z contrast agent bulks overestimates electron densities. Consequently, HU-based dose calculations result in a higher delivered dose than expected from the treatment planning system.

J Contemp Brachytherapy 2022; 14, 1: 80–86
DOI: https://doi.org/10.5114/jcb.2022.113551

**Key words:** dose calculation, contrast agent, TG-186, Hounsfield unit, electron density.

Purpose

Interstitial and intracavitary brachytherapy treatment is most commonly planned, based on computed tomography (CT) scans of patients with implanted catheters or applicators. Most clinical treatment plans are still calculated according to the classical TG-43 formalism, using a line source and anisotropic dose function in pure water [1, 2]. However, dose information regarding Hounsfield unit (HU)-related electron density information from CT scans arouse growing interest in clinical routine.

Recent algorithms of commercial treatment planning systems (TPS), such as Oncentra®Brachy (Elekta AB, Sweden) or BrachyVision™ (Varian Medical Systems Inc., USA) [3-8] allow for more sophisticated calculations considering variable electron densities with individual radiation scattering and absorption functions. These so-called ‘model-based dose calculation algorithms’ (MBDCA) are designed for clinical use following the guidelines of TG-186 report [3]. MBDCA either use CT numbers (i.e., Hounsfield unit-based electron densities) or manually assigned electron densities for specific tissues or materials in irradiated regions of interest (ROI). Oncentra®Brachy TPS supports manual density allocation, with a limited number of pre-defined material types as well as CT-based electron density and mass density conversion, with a HU-related lookup table according to a method of Knöös, Nilsson, and Ahlgren [9] (which is only limited to a HU maximum of 3365 in the software). This electron density conversion formalism is intended for human tissue due to a limitation that it assumes only a minor content of high atomic number materials (high-Z). It is not

Address for correspondence: Christian Scherf, Department of Radiation Oncology, University Hospital, Goethe University, Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany, phone: +49-69-6301-84344, fax: +49-69-6301-5538, e-mail: Christian.Scherf@kgu.de

Received: 08.11.2021
Accepted: 03.01.2022
Published: 18.02.2022
designed for application with metal implants and other high-Z materials with HU ≥ 1000 [9], as most X-ray concentrated contrast agents. However, iodinated contrast agents may be requested for treatment planning CT scans to enhance visibility of tumors and organs at risk. The presence of contrast agents will affect HU numbers and consequently HU-based TG-186 dose calculations.

Previous investigations have already shown the measurable dosimetric effects of radiographic contrast agents in balloon applicators and catheter heterogeneities [8, 11-16]. A 2 cm phantom layer filled with 367 mg/cm³ iodine concentration instead of water between iridium-192 (192Ir) high-dose-rate (HDR) source and parallel plate ion chamber, resulted in a relative dose reduction down to 90% and 91% in the measured dose and Monte Carlo calculations, respectively [13]. Model-based calculation instead of TG-43 formalism close to steel catheters inside a breast implant target volume significantly reduced the calculated volume, receiving 150% and 200% (V150% and V200%) [8]. Contrast agents may also be applied for intended dose sparing of organs at risk, up to 15% (bladder and rectum walls in vaginal balloon packing) [16].

In this study, we investigated the effect of contrast agent in the surrounding of the brachytherapy source. A phantom model was applied to evaluate the impact on the dose to specific ROI for interstitial implants, and HU-based dose calculation with significant concentrations of contrast agent was used for CT imaging. The effect of diluted contrast agent on electron densities and dose calculations for 192Ir brachytherapy source was compared with the measured dose in the presence of contrast agent. The effects were demonstrated in a water phantom model with an interior reservoir filled with diluted contrast agent.

Material and methods

Phantom and study design

A phantom with a water-filled polyethylene box was used to examine dose calculations and dose measurements based on CT scans (Figure 1). To simulate the presence of iodinated contrast agent inside a specific ROI, a reservoir was centrally placed in the phantom and filled with 700 cm³ diluted iodinated contrast agent. The commercial contrast agent Imeron® 350 (Bracco Imaging S.p.A, Italy) mainly consists of iomeprol with 350 mg iodine concentration per ml. Imeron® 350 was diluted with distilled water to obtain concentrations of 25, 50, 100, 200, and 300 mg iodine per ml. Pure water (0 mg/ml iodine concentration) was used as a reference. A 1.9 mm interstitial brachytherapy steel needle was centrally positioned in the reservoir, and a small PinPoint® ionization chamber (PTW, Freiburg, Germany) was used to measure relative dose.

Computed tomography

Computed tomography images of the phantom were acquired with a Philips Brilliance Big Bore Oncology CT scanner at 120 kV, with a typical pelvis brachytherapy protocol using 204 mA tube current (250 mAs). Image reconstruction from helical data was done for 1.5 mm slice thickness for further use with Oncentra®Brachy TPS. Scans were performed with pure water and the diluted contrast agent up to 300 mg/ml iodine.

The CT numbers for the diluted contrast agent were obtained by evaluating rectangular ROIs of 1980 CT voxels (925 mm²) within the centrally located reconstructed slice of the phantom (Figure 2). Electron densities ρe(CT) used in the treatment planning system were based on this equation [10].

\[ \rho_{e(CT)} = (A + B \times HU \times 10^{-3}) \times 10^{23} \text{ cm}^{-3} \] (Eq. 1),

with A = 3.30 and B = 3.40 for –1000 < HU < 150, and A = 3.65 and B = 1.22 for 150 < HU < 1000. The relationship between HU and ρe used in the treatment planning system was based on this equation [10].

To compare the diluted contrast agent (contains iodine as high-Z chemical element) with human tissue (only low- and medium-Z chemical elements), four selected tissue equivalent materials from a Gammex 467 tis-
Calculation of electron densities from chemical structure

In addition, a second approach was used to derive electron densities $\rho_{e(\text{calc})}$ from chemical composition of a compound. For each concentration of diluted contrast agent, the parts of iomeprol and water were calculated, including mass densities and relative fractions of chemical elements, as it was explained by Seco and Evans [17]:

$$\rho_{e(\text{calc})} = \frac{\rho_m}{u} \times \sum f_i \times \left(\frac{Z}{A}\right)_i$$

(Eq. 2)

with the mass density of the compound $\rho_m$, the atomic mass unit $u$, the atomic number to atomic weight ratios of the chemical elements $\sum f_i \times \left(\frac{Z}{A}\right)_i = <Z/A>$ summed over their mass fractions $f_i$.

According to the manufacturer specification, Imeron® 350 with 350 mg/ml iodine concentration contains 71.44 g iomeprol per 100 cm³. For further calculations, it was assumed that the contrast agent dilutions only consist of iomeprol (C₁₇H₂₂I₃N₃O₈, molar weight 777.087 u, mass density 2.27 g/cm³ [18]) and water (H₂O, molar weight 18.015 u). Low concentrated other ingredients of Imeron®, like trometamol and hydrochloric acid, were neglected in calculations. Contrast agent and water were mixed in different ratios, as presented in Table 1, with their resulting mass densities $\rho_m$ and weighted sums of $<Z/A>$.

Electron densities $\rho_{e(\text{calc})}$ of Gammex 467 tissue-like compounds were calculated based on their chemical compositions, published by Landry et al. [19].

Dose measurements and CT-based collapsed cone dose calculations

Dose calculations and dose measurements were performed in the same setup for one $^{192}$Ir single-source position in the center of the reservoir. Radial dose distribution was calculated for each dilution using corresponding CT data set. A set of dose points from 1.0 mm up to 30.0 mm distances perpendicular to the center of the source axis was defined for the calculations. For measurements, the set of dose points started from 3.1 mm due to geometrical limitation. Smaller distances were not possible, as the needle and the ion chamber were in touch at a distance of 3.1 mm between their central axes.

Dose measurements were carried out in the above-described phantom placed inside a tank of MP3 motorized water phantom system (PTW, Freiburg, Germany), similarly described by Rossi et al. [20]. Iridium-192 source of Elekta Flexitron® afterloader was positioned in the geometric center of the contrast agent reservoir according to Figure 1 for each measured set of points. A small PTW 31016 PinPoint® chamber was automatically moved by the motorized system perpendicular to Flexisource axis in 0.5 mm steps within the contrast agent reservoir. Dose-rate was integrated
for 5 seconds per step using a TANDEM electrometer and MEPHYSTO mc² software (PTW, Freiburg, Germany).

These axial dose point measurements were acquired for water and all contrast agent dilutions. The effect of source position fluctuations was minimized according to Schoenfeld et al. [21] by searching a maximum dose-rate position in Y and Z directions for every source cycle, with 0.1 mm step resolution.

The measured data of different contrast agent concentrations were always evaluated relative to the measured pure water data as reference. This enabled us to assess the data independently of calibration effects and correction factors. PinPoint® chamber, with a volume of 0.015 cm³ has an almost constant relative response (variation < 1%) with respect to expected radial variation of the mean photon energy [22]. Therefore, an impact to the measured dose related to additional beam hardening due to the presence of iodine, can be neglected. Thus, all known correction factors for volume averaging, position of the chamber’s effective point of measurement, and radiation quality [21] resulted in the value of 1.

Finally, the relative consideration of measured and calculated data eliminated the dominating geometrical 1/r² dependency and small attenuation factor of the steel needle (~1.7%) in all evaluations and from the graphs in Figures 3 and 4.

Dose calculations were performed with ACE collapsed cone algorithm of Oncentra®Brachy [4]. TPS was commissioned based on the published consensus data of Flexisource [23]. Mass density was HU dependently assigned to each voxel of 3D-CT data, with a lookup table

| Iodine concentration | Volume fraction Imeron® 350 [%] | Volume fraction water [%] | Weight fraction iomeprol [g/cm³] | Weight fraction water [g/cm³] | Mass density ρm [g/cm³] | <Z/A> |
|----------------------|---------------------------------|---------------------------|-------------------------------|-----------------------------|------------------------|--------|
| 0 mg/ml (pure water) | 0.0                             | 100.0                     | 0.0                           | 0.998                       | 0.998                  | 0.5551 |
| 25 mg/ml             | 7.1                             | 92.9                      | 0.051                         | 0.976                       | 1.027                  | 0.5510 |
| 50 mg/ml             | 14.3                            | 85.7                      | 0.102                         | 0.953                       | 1.055                  | 0.5472 |
| 100 mg/ml            | 28.6                            | 71.4                      | 0.204                         | 0.908                       | 1.112                  | 0.5401 |
| 200 mg/ml            | 57.1                            | 42.9                      | 0.408                         | 0.819                       | 1.227                  | 0.5280 |
| 300 mg/ml            | 85.7                            | 14.3                      | 0.612                         | 0.729                       | 1.341                  | 0.5178 |
| 350 mg/ml (pure Imeron® 350) | 100.0                         | 0.0                       | 0.714                         | 0.684                       | 1.398                  | 0.5134 |

**Table 1.** Volume ratios used to prepare different iodine concentrations, followed by their calculated mass densities (at 20°C) and mean Z/A values. Pure water and pure Imeron® 350 are also listed. Only iomeprol and water were considered in these calculations, and molecular interaction effects to the volume of the liquid mixture were neglected.

**Fig. 3.** A) Results of dose point calculations in the TPS for pure water and diluted contrast agent in the reservoir. All collapsed cone ACE data was calculated HU-based with corresponding CT data starting at the applicator surface. B) Results of dose point measurements with PinPoint® ionization chamber, starting at the closest possible distance. All data are relatively normalized to the dose measured in pure water.
that applies the method of Knöös et al. [9] as described in the CT section. Dose was calculated with high accuracy level of the software, applying 1 × 1 × 1 mm³ voxels in a 10 cm bounding box, and 2 × 2 × 2 mm³ voxels in a 20 cm bounding box, based on isocenter of the active dwell position [4, 5].

Results

Electron densities derived from CT and calculated from chemical structure

The electron densities derived from both approaches, i.e. obtained from CT and calculated from chemical compositions, are shown in Table 2 and illustrated in Figure 5.

The measured mean HU\textsubscript{CT} numbers obtained from CT scans and their derived electron densities of the contrast agent dilutions and of the selected tissue equivalent materials, are also listed in Table 2. Reduced X-ray transmission related to higher iodine concentrations resulted in increasing standard deviation and saturation effects of the determined HU values. According to Equation 1, for both, diluted contrast agent and phantom materials, electron densities and electron densities relative to water were calculated. The mass densities and the calculated electron densities that were obtained from the chemical compositions were calculated by applying Equation 2.

Both approaches yielded different values for electron densities. The comparison of contrast agent dilutions showed significant higher values for the HU-based electron densities. With increasing iodine concentration, the relative deviation ranged from +24% for 25 mg/ml, up to +65% for 300 mg/ml. The CT derived relative electron densities obtained from Gammex phantom materials showed only moderate deviations from the calculated values. Their relative deviations ranged from −5.5% for the SB3 cortical bone, up to +3.1% for the LV1-liver equivalent phantom material.

Dose point evaluation

Figure 3A demonstrates dependency of the calculated dose as a function of the radial source distance and of the iodine concentration. Each set of dose points for the diluted contrast agent was calculated relative to the corresponding set of dose points in water. In consequence, the radial 1/\(r^2\) decay was cancelled out in the diagram.

Figure 3B shows dependency of the measured dose as a function of the radial source distance and the iodine concentration. Each set of dose points for the diluted contrast agent was calculated relative to the corresponding set of dose points in water. In consequence, the radial 1/\(r^2\) decay was cancelled out in the diagram.

Table 2. Measured HU numbers (HU\textsubscript{CT}) and derived electron densities (\(\rho\textsubscript{e,CT}\)), absolute and relative to water of the contrast agent dilutions and selected Gammex phantom materials. Standard deviations result from statistical evaluation of CT data. Mass densities (\(\rho\textsubscript{m}\)) and calculated electron densities (\(\rho\textsubscript{e,calc}\)) of each atomic composition, absolute, and relative to water

| Iodine concentration and phantom material | HU\textsubscript{CT} (120 kV) | \(\rho\textsubscript{e,CT}\) [10\textsuperscript{23} cm\textsuperscript{-3}] | \(\rho\textsubscript{e,CT}\) relative to water | \(\rho\textsubscript{m}\) [g/cm\textsuperscript{3}] | \(\rho\textsubscript{e,calc}\) [10\textsuperscript{23} cm\textsuperscript{-3}] | \(\rho\textsubscript{e,calc}\) relative to water |
|-----------------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Contrast agent                          |                 |                 |                 |                 |                 |                 |
| 0 mg/ml (pure water)                    | 2 ±8            | 3.31 ±0.03      | 1.00 ±0.01      | 0.998           | 3.340           | 1.000           |
| 25 mg/ml                                | 453 ±21         | 4.20 ±0.03      | 1.27 ±0.01      | 1.027           | 3.415           | 1.021           |
| 50 mg/ml                                | 793 ±38         | 4.62 ±0.05      | 1.40 ±0.01      | 1.055           | 3.483           | 1.042           |
| 100 mg/ml                               | 1283 ±60        | 5.22 ±0.07      | 1.58 ±0.02      | 1.112           | 3.620           | 1.085           |
| 200 mg/ml                               | 2129 ±142       | 6.25 ±0.17      | 1.89 ±0.03      | 1.227           | 3.901           | 1.169           |
| 300 mg/ml                               | 2623 ±221       | 6.85 ±0.27      | 2.07 ±0.04      | 1.341           | 4.179           | 1.254           |
| Gammex                                  |                 |                 |                 |                 |                 |                 |
| LV1-liver                               | 93 ±17          | 3.62 ±0.06      | 1.10 ±0.02      | 1.096           | 3.560           | 1.067           |
| CB2-30% CaCO\textsubscript{3}           | 513 ±22         | 4.28 ±0.03      | 1.30 ±0.01      | 1.331           | 4.268           | 1.279           |
| CB2-50% CaCO\textsubscript{3}           | 915 ±25         | 4.77 ±0.03      | 1.44 ±0.01      | 1.559           | 4.911           | 1.472           |
| SB3 cortical bone                       | 1376 ±29        | 5.33 ±0.04      | 1.61 ±0.01      | 1.822           | 5.666           | 1.698           |
Effects of iodinated contrast agent on HU-based dose calculation and dose delivered in iridium-192 high-dose-rate brachytherapy

In clinical treatment planning, contrast agents are widely used to enhance visualization of soft tissue. This study showed that the presence of iodinated contrast agent affected model-based dose calculations if electron densities derived from HU numbers were used for treatment planning. The electron densities of all contrast agent dilutions obtained from CT data were significantly higher than the calculated values from the chemical composition. These deviations were related to CT X-ray spectrum that was dominated by lower energy photons. They mainly interact with matter through photo-electric effect, in particular with high-Z elements, due to prominent Z^4 dependence. Due to the resulting high X-ray attenuation for iodine and other high-Z materials, the electron densities derived from CT data are overestimated. This also results in an overestimation of attenuation for 192Ir radiation quality. These facts are in accordance with the general Monte Carlo simulations of radiation energy-dependence of mass attenuation coefficients (µ/ρ), and the effective electron densities for different iodinated contrast agents published by Al-Buriahi and Tonguc [24].

Because of the overestimated densities derived from HU, dose calculation algorithm falsely assumes a too strong photon interaction with the matter. This results in a stronger calculated photon attenuation and mass energy absorption and consequently, manifests itself in a too steep depth dose gradient. The relative deviation between measurement and calculation increases with increasing iodine concentration and deeper penetration into the contrast bulk. Measured dose was always higher than the corresponding HU-based calculation.

From the clinical perspective, this leads in the case of substantially concentrated contrast agent in a risk structure, to an actual higher dose exposure than indicated in treatment plan, which can increase the risk of undesirable side effects. In the case of concentrated contrast agent in clinical target volume, the dose underestimation manifests itself in extended calculated dwell times, i.e., the treated dose will exceed the intended dose of all target volumes and risk structures.

When contrast agent is used to visualize tumor-related information, such as soft tissue and lymph nodes, the typical iodine concentration in CTV does not exceed 25 mg/ml (i.e., 450 HU) when planning CT data is acquired. In such cases, the deviation of ACE calculated and delivered dose will differ in less than 2% at ≤ 10 mm source distance, and might be of minor importance for a clinical outcome.

The error in dose calculation should be considered relevant from 450 HU. In such rare situations, a manual assignment of associated tissue type (i.e., without considering contrast agent) or even of water is more appropriate. For one thing, the actually measured differences according to Figure 3B were always less prominent than the HU-based calculated differences, as shown in Figure 3A. Furthermore, the measured dose and the dose to water in Figure 3B differ significantly less than the corresponding HU-based calculated dose and the measured dose, as presented in Figure 4. On the other hand, the relevant contrast agent influence in most clinical situations becomes even smaller due to physiologically-induced decrease in concentration with advancing time between CT acquisition and radiation treatment.

Conclusions

The present work demonstrates that the standard HU to electron density conversion formalism of Oncentra®Brachy ACE algorithm overestimates the electron densities of diluted iodinated contrast agent. In presence of contrast agent, the delivered dose will be higher than the corresponding calculated dose. Under such circumstances, the user should keep in mind that HU-based dose calculations will result in erroneous dose information. A discrepancy of 2% to 7% per each 10 mm penetration depth depending on the contrast agent concentration from 25 mg/ml (450 HU) to 300 mg/ml (2600 HU) can be estimated.
Disclosure

The authors report no conflict of interest.

References

1. Nath R, Anderson LL, Luxton G et al. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 1995; 22: 209-234.

2. Rivard MJ, Coursey BM, DeWerd LA et al. Update of AAPM task group no. 43 report: a revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004; 31: 633-674.

3. Beaulieu L, Tedgren AC, Carrier JF et al. Report of the Task Group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: Current status and recommendations for clinical implementation. Med Phys 2012; 39: 6208-6236.

4. van Veelen B, Ma Y, Beaulieu L. ACE advanced collapsed cone engine. White Paper 2014; Elekta AB, Stockholm, Sweden.

5. Ma Y, Lacroix F, Lavallée MC, Beaulieu L. Validation of the Oncentra Brachy Advanced Collapsed cone Engine for a commercial $^{192}$Ir source using heterogeneous geometries. Brachytherapy 2015; 14: 939-952.

6. Rivard MJ, Beaulieu L, Mourtada F. Enhancements to commissioning techniques and quality assurance of brachytherapy treatment planning systems that use model-based dose calculation algorithms. Med Phys 2010; 37: 2645-2658.

7. Papagiannis P, Pantelis E, Karaiskos P. Current state of the art brachytherapy treatment planning dosimetry algorithms. Br J Radiol 2014; 87: 20140163.

8. Sinnatamby M, Nagarajan V, Reddy KS et al. Dosimetric comparison of Acuros™ BV with AAPM TG43 dose calculation formalism in breast interstitial high-dose-rate brachytherapy with the use of metal catheters. J Contemp Brachytherapy 2015; 7: 273-279.

9. Knöös T, Nilsson M, Ahlgren L. A method for conversion of Hounsfield number to electron density and prediction of macroscopic pair production cross-sections. Radiother Oncol 1986; 5: 337-345.

10. Oncentra Brachy 4.6, Physics and Algorithms Manual, Elekta AB 2018, Stockholm, Sweden.

11. Williamson JF, Perera H, Li Z, Lutz WR. Comparison of calculated and measured heterogeneity correction factors for 125I, 137Cs, and $^{192}$Ir brachytherapy sources near localized heterogeneities. Med Phys 1993; 20: 209-222.

12. Kassas B, Mourtada F, Horton JL, Lane RG. Contrast effects on dosimetry of a partial breast irradiation system. Med Phys 2004; 31: 1976-1979.

13. Kirk MC, Hsi WC, Chu JCH et al. Dose perturbation induced by radiographic contrast inside brachytherapy balloon applicators. Med Phys 2004; 31: 1219-1224.

14. Cheng CW, Mitra R, Allen Li X, Das JJ. Dose perturbations due to contrast medium and air in MammoSite® treatment: An experimental and Monte Carlo study. Med Phys 2005; 32: 2279-2287.

15. Oh S, Scott J, Shin DH et al. Measurements of dose discrepancies due to inhomogeneities and radiographic contrast in balloon catheter brachytherapy. Med Phys 2009; 36: 3945-3954.

16. Saini AS, Zhang GG, Finkelstein SE, Biagioli MC. Dose reduction study in vaginal balloon packing filled with contrast for HDR brachytherapy treatment. Int J Radiat Oncol Biol Phys 2011; 80: 1263-1267.

17. Seco J, Evans PM. Assessing the effect of electron density in photon dose calculations. Med Phys 2006; 33: 540-552.

18. https://comptox.epa.gov/dashboard/dsstoxdb/results?utf8=%E2%9C%93&search=Iomeprol (accessed October 25th, 2021).